Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study in Healthy Children of GSK Biologicals' DTPa-IPV/Hib-MenC-TT Vaccine, GSK2197870A, co-Administered With Prevenar as a Three-Dose Primary Vaccination Course in Infancy Followed by a Booster Dose of Menitorix at 12 Months of Age.

Next Previous
Search
Trial Profile

Study in Healthy Children of GSK Biologicals' DTPa-IPV/Hib-MenC-TT Vaccine, GSK2197870A, co-Administered With Prevenar as a Three-Dose Primary Vaccination Course in Infancy Followed by a Booster Dose of Menitorix at 12 Months of Age.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-DTaP-poliovirus-meningococcal vaccine group C conjugate (Primary) ; Hib-DTaP-poliovirus vaccine; Hib-meningococcal vaccine group C conjugate; Meningococcal vaccine group A conjugate; Meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Meningococcal group C infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics

    • Most Recent Events

    • 06 Jun 2018 Biomarkers information updated
    • 23 Jan 2013 Primary endpoint 'Immunological-response' has been met.
    • 22 Dec 2010 Actual end date (1 Dec 2010) added as reported by ClinicalTrial.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top